OYSTER POINT PHARMACEUTICALS

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

#SimilarOrganizations #People #Financial #Website #More

OYSTER POINT PHARMACEUTICALS

Social Links:

Facebook

Linkedin

Twitter

Industry:

Biopharma Clinical Trials Health Care Medical Pharmaceutical

Founded:

2015-01-01

Address:

San Francisco, California, United States

Country:

United States

Website Url:

http://www.oysterpointrx.com

Total Employee:

11+

Status:

Active

Email Addresses:

[email protected]

Total Funding:

235.8 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins

Similar Organizations

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Current Advisors List

jeffrey-nau_image

Jeffrey Nau Board Member @ Oyster Point Pharmaceuticals
Board_member

clare-ozawa_image

Clare Ozawa Board Member @ Oyster Point Pharmaceuticals
Board_member

ali-behbahani_image

Ali Behbahani Board Member @ Oyster Point Pharmaceuticals
Board_member

mark-murray_image

Mark Murray Board Member @ Oyster Point Pharmaceuticals
Board_member

william-j-link_image

William J. Link Board Member @ Oyster Point Pharmaceuticals
Board_member

michael-ackermann_image

Michael Ackermann Board Chairman @ Oyster Point Pharmaceuticals
Board_member
2017-10-01

Current Employees Featured

not_available_image

Donald J. Santel
Donald J. Santel Non-executive Chairperson, Director @ Oyster Point Pharmaceuticals
Non-executive Chairperson, Director
2021-07-01

michael-ackermann_image

Michael Ackermann
Michael Ackermann Chairman @ Oyster Point Pharmaceuticals
Chairman
2017-10-01

loni-da-silva_image

Loni da Silva
Loni da Silva Senior Vice President, Regulatory Affairs @ Oyster Point Pharmaceuticals
Senior Vice President, Regulatory Affairs

mark-murray_image

Mark Murray
Mark Murray CFO @ Oyster Point Pharmaceuticals
CFO

jeffrey-nau_image

Jeffrey Nau
Jeffrey Nau CEO @ Oyster Point Pharmaceuticals
CEO
2017-03-01

patricia-johnson_image

Patricia Johnson
Patricia Johnson Executive Director, Regulatory CMC @ Oyster Point Pharmaceuticals
Executive Director, Regulatory CMC
2018-04-01

john-snisarenko_image

JOHN SNISARENKO
JOHN SNISARENKO Chief Commercial Officer @ Oyster Point Pharmaceuticals
Chief Commercial Officer

puja-shah_image

Puja Shah
Puja Shah Medical Director @ Oyster Point Pharmaceuticals
Medical Director
2020-12-01

daniel-lochner_image

DANIEL LOCHNER
DANIEL LOCHNER Chief Financial Officer @ Oyster Point Pharmaceuticals
Chief Financial Officer

Founder

jeffrey-nau_image

Jeffrey Nau

mark-murray_image

Mark Murray

Stock Details

Company's stock symbol is NASDAQ:OYST

Investors List

flying-l-partners_image

Flying L Partners

Flying L Partners investment in Series B - Oyster Point Pharmaceuticals

vida-ventures_image

Vida Ventures

Vida Ventures investment in Series B - Oyster Point Pharmaceuticals

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series B - Oyster Point Pharmaceuticals

invus_image

Invus

Invus investment in Series B - Oyster Point Pharmaceuticals

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series B - Oyster Point Pharmaceuticals

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series A - Oyster Point Pharmaceuticals

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series A - Oyster Point Pharmaceuticals

Official Site Inspections

http://www.oysterpointrx.com Semrush global rank: 3.82 M Semrush visits lastest month: 3.47 K

Host Informations
Whois Informations

Loading ...

More informations about "Oyster Point Pharmaceuticals" on Search Engine